Non-red blood cell transfusion as a risk factor for mortality following percutaneous coronary intervention

International Journal of Cardiology

Volumn 157, Issue 2, 2012, Pages 169-173

  Robinson, Simon D ^a   Janssen, Christian ^a,b   Fretz, Eric B ^a   Chase, Alex J ^c   Siega, Anthony Della ^a   Carere, Ronald G ^d   Fung, Anthony ^e   Simkus, Gerald ^f   Hilton, J David ^a   Berry, Brian ^a,g   Klinke, W Peter ^a  

^a Victoria Heart Institute Foundation   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MORRISTON HOSPITAL   (United Kingdom)

^d ST PAUL S HOSPITAL   (Canada)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

^f ROYAL COLUMBIAN HOSPITAL   (Canada)

^g ROYAL JUBILEE HOSPITAL   (Canada)

Author keywords

Mortality; Percutaneous coronary intervention; Transfusion

Indexed keywords

AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ERYTHROCYTE TRANSFUSION; PERCUTANEOUS CORONARY INTERVENTION; PLASMA TRANSFUSION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE TRANSFUSION;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLASMA; PLATELET TRANSFUSION; RISK FACTORS; SURVIVAL RATE;

EID: 84861094200     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.12.013     Document Type: Article

References (31)

1. C.P. Cannon, W.S. Weintraub, and L.A. Demopoulos Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 2001 1879 1887
2. L. Wallentin, B. Lagerqvist, S. Husted, F. Kontny, E. Stahle, and E. Swahn Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease Lancet 356 2000 9 16
3. SYNERGY Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
4. T.D. Kinnaird, E. Stabile, and G.S. Mintz Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Am J Cardiol 92 2003 930 935
5. G. Ndrepepa, P.B. Berger, and J. Mehilli Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point J Am Coll Cardiol 51 2008 690 697
6. G. Maluenda, G. Lemesle, and I. Ben-Dor Value of blood transfusion in patients with a blood hematocrit of 24% to 30% after percutaneous coronary intervention Am J Cardiol 104 2009 1069 1073
7. A.J. Chase, E.B. Fretz, and W.P. Warburton Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) Heart 94 2008 1019 1025
8. C.G. Koch, L. Li, and D.I. Sessler Duration of red-cell storage and complications after cardiac surgery N Engl J Med 358 2008 1229 1239
9. H. Khan, J. Belsher, and M. Yilmaz Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients Chest 131 2007 1308 1314
10. B.D. Spiess, D. Royston, and J.H. Levy Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes Transfusion 44 2004 1143 1148
11. K. Karkouti, D.N. Wijeysundera, and T.M. Yau Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery Can J Anaesth 53 2006 279 287
12. T. McGrath, C.G. Koch, and M. Xu Platelet transfusion in cardiac surgery does not confer increased risk for adverse morbid outcomes Ann Thorac Surg 86 2008 543 553
13. R.B. D'Agostino Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
14. E.H. Blackstone Comparing apples and oranges J Thorac Cardiovasc Surg 123 2002 8 15
15. S.V. Rao, J.G. Jollis, and R.A. Harrington Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562
16. P.C. Hebert, G. Wells, and M.A. Blajchman A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group N Engl J Med 340 1999 409 417
17. E. Karvouni, D.G. Katritsis, and J.P.A. Ioannidis Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J Am Coll Cardiol 41 2003 26 32
18. G.W. Stone, B. Witzenbichler, and G. Guagliumi Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
19. A.M. Gori, R. Marcucci, and A. Migliorini Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents J Am Coll Cardiol 52 2008 734 739
20. R. Marcucci, D. Brogi, and F. Sofi PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting Heart 92 2006 377 381
21. R. Norda, E. Tynell, and O. Akerblom Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet transfusion in Europe J Trauma 60 2006 S41 S45
22. C.C. Silliman, L.K. Boshkov, and Z. Mehdizadehkashi Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors Blood 101 2003 454 462
23. P.M. Ridker, N. Rifai, M. Pfeffer, F. Sacks, S. Lepage, and E. Braunwald Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction Circulation 101 2000 2149 2153
24. N. Blumberg, J. Heal, G. Hicks, and W. Risher Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery Transfusion 41 2001 790 793
25. D.F. O'Shaughnessy, C. Atterbury, and P.B. Maggs Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant Br J Haematol 126 2004 11 28
26. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-frozen plasma, cryoprecipitate, and platelets administration practice guidelines development Task Force of the College of American Pathologists JAMA 271 1994 777 781
27. T.W. Meade, V. Ruddock, Y. Stirling, R. Chakrabarti, and G.J. Miller Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study Lancet 342 1993 1076 1079
28. R. Virmani, F.D. Kolodgie, A. Farb, and A. Lafont Drug eluting stents: are human and animal studies comparable? Heart 89 2003 133 138
29. J. Metz, K.M. McGrath, and M.L. Copperchini Appropriateness of transfusions of red cells, platelets and fresh frozen plasma. An audit in a tertiary care teaching hospital Med J Aust 162 572-573 1995 576 577
30. J.B. Holcomb, C.E. Wade, and J.E. Michalek Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients Ann Surg 248 2008 447 458
31. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2